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Background: Breast and prostate cancers are the most commonly diagnosed non-dermatologic malignancies in
Canada. Agents including endocrine therapies (e.g., aromatase inhibitors, gonadotrophin-releasing hormone
analogs, anti-androgens, tamoxifen) and chemotherapy have improved survival for both conditions. As endocrine
manipulation is a mainstay of treatment, it is not surprising that hot flashes are a common and troublesome
adverse effect. Hot flashes can cause chills, night sweats, anxiety, and insomnia, lessening patients’ quality of life.
These symptoms impact treatment adherence, worsening prognosis. While short-term estrogen replacement
therapy is frequently used to manage hot flashes in healthy menopausal women, its use is contraindicated in breast
cancer. Similarly, testosterone replacement therapy is contraindicated in prostate cancer. It is therefore not
surprising that non-hormonal pharmacological treatments (anti-depressants, anti-epilectics, anti-hypertensives),
physical/behavioral treatments (e.g., acupuncture, yoga/exercise, relaxation techniques, cognitive behavioral
therapy), and natural health products (e.g., black cohosh, flax, vitamin E, ginseng) have been studied for control of
hot flashes. There is a need to identify which interventions minimize the frequency and severity of hot flashes and
their impact on quality of life. This systematic review and network meta-analysis of randomized studies will
synthesize available evidence addressing this knowledge gap.
Methods/design: An electronic search of Medline, Embase, AMED, PsycINFO, and the Cochrane Register of
Controlled Trials has been designed by an information specialist and peer reviewed by a second information
specialist. Study selection and data collection will be performed by two reviewers independently. Risk of bias
assessments will be completed using the Cochrane Risk of Bias Scale. Outcomes of interest will include validated
measures of hot flash severity, hot flash frequency, quality of life, and harms. Bayesian network meta-analyses will
be performed where judged appropriate based on review of clinical and methodologic features of included studies.
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Discussion: Our review will include a broad range of interventions that patients with breast and prostate cancer
have attempted to use to manage hot flashes. Our work will establish the extent of evidence underlying these
interventions and will employ an inclusive approach to analysis to inform comparisons between them. Our findings
will be shared with Cancer Care Ontario for consideration in the development of guidance related to supportive
care in these patients.
Systematic review registration: PROSPERO: CRD42015024286
Keywords: Breast cancer, Prostate cancer, Hot flash, Systematic review, Network meta-analysisBackground
Breast and prostate cancers are the most commonly diag-
nosed non-dermatologic malignancies in Canada, with over
23,000 women and 23,000 men diagnosed annually [1, 2].
Agents including endocrine therapies (e.g., aromatase in-
hibitors, gonadotrophin-releasing hormone analogs, anti-
androgens, and tamoxifen), endocrine manipulations (e.g.,
surgical ovarian removal), and chemotherapy (with result-
ing premature ovarian failure) have improved survival for
both conditions. As endocrine manipulation is the mainstay
of treatment for both diseases, it is not surprising that hot
flashes are a troublesome side effect in two of every three
patients receiving endocrine therapy [3]. Hot flashes are a
vasomotor symptom which lessens patients’ quality of life
given that they cause chills, night sweats, and irregular
heartbeat and can cause compromised sleep and insomnia
[4–6]. They can be a challenge for years. These symptoms
impact adherence to treatment, with non-adherence rates
as high as 55 %, and can therefore worsen prognosis [4].
While estrogen replacement therapy (ERT) is often used
for hot flashes in healthy menopausal women, its use is
contraindicated in breast cancer [7]. Similarly, testos-
terone replacement therapy (TRT) is contraindicated in
prostate cancer [8–10]. Hence, non-hormonal pharmaco-
logical treatments (e.g., anti-depressants, anti-epilectics,
anti-hypertensives), physical/behavioral treatments (e.g.,
yoga/exercise, relaxation techniques, cognitive behav-
ioral therapy), acupuncture, and natural health prod-
ucts (e.g., black cohosh, flax, vitamin E, ginseng) have
been studied for control of hot flashes [11–13]. Estab-
lishing which non-hormonal treatments can minimize
the frequency and severity of hot flashes and their im-
pact on quality of life is vital for prostate and breast
cancer survivors. We will perform a systematic review
with network meta-analyses to address the following
question: In breast cancer and prostate cancer survi-
vors, what are the relative benefits of non-hormonal
therapies on (1) frequency and severity of hot flashes?
(2) quality of life? (3) quality of life related to depres-
sion and sleep quality? While past reviews have consid-
ered some of these treatments in isolation, there is a
need for network meta-analyses [14–16] to compare
many alternatives in a unified analysis.Methods/design
This protocol has been registered within the PROSPERO
database for systematic reviews (CRD42015024286).Data sources and search for studies
The search strategy has been developed and tested
through an iterative process by an experienced medical
information specialist in consultation with the review
team. Using the OVID platform, we will search Ovid
MEDLINE®, Ovid MEDLINE® In-Process & Other Non-
Indexed Citations, Embase, AMED, and PsycINFO. We
will also search the CENTRAL database using the
Cochrane Library on Wiley. Strategies will utilize a
combination of controlled vocabulary (e.g., “Breast
Neoplasms,” “Prostatic Neoplasms,” “Hot Flashes”) and
keywords (e.g., breast cancer, prostate cancer, vaso-
motor symptoms). Vocabulary and syntax will be adjusted
across databases. No language or date restrictions will
be applied. We will use a validated randomized con-
trolled trial filter and will remove animal-only and
opinion-pieces from the results. The core strategy will
be reviewed prior to execution by another senior infor-
mation specialist using the Peer Review for Electronic
Search Strategies checklist [17]. We will search the
World Health Organization’s ICTRP Search Portal and
www.ClinicalTrials.gov for randomized controlled trials
and will also hand-search the bibliographies of pertin-
ent references. Specific details regarding the strategies
appear in Additional file 1.Study eligibility criteria
Studies fulfilling the following PICOS (Population-
Intervention-Comparators-Outcomes-Study design) criteria
will be selected for inclusion in this review.Population
Studies involving patients diagnosed with breast cancer
or prostate cancer and who are experiencing hot flashes
will be sought. No restrictions on age or cancer stage
will be used.
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Studies evaluating the effects of non-hormonal pharma-
cologic, behavioral/physical, and natural health product
interventions will be considered. Eligible pharmacologic
interventions will include anti-depressants from the se-
lective serotonin reuptake inhibitors (SSRI) class (e.g.,
sertraline, escitalopram, citalopram, and so forth) and
selective norepinephrine reuptake inhibitor (SNRI) class
(e.g., venlafaxine, duloxetine, and so forth), as well as
certain neuroleptic agents (gabapentin, clonidine) and
anti-hypertensive medications (e.g., alpha blockers, beta
blockers). All doses and formulations will be eligible.
Structured physical/behavioral interventions of interest
will include acupuncture, yoga, exercise programs, hyp-
nosis, relaxation techniques, and cognitive behavioral
therapy. Nutritional healthcare products of interest will
include vitamin E, flax, ginseng, black cohosh, isofla-
vones, menerba, and soy. All doses and formulations will
be eligible. Lastly, placebo and no treatment will be eli-
gible given their high likelihood of being links to indirect
evidence in the treatment network. We will treat them as
separate interventions in our analyses. After discussion
with the clinical and statistical experts on the team, the
nodes will be finalized to maximize clinical relevance. ForFig. 1 Interventions eligible for network meta-analyses in the review. The c
interventions, blue = natural health products, and green = physical activitie
between treatments. Which comparisons have been studied will be establishe
structure. Network refinement to reflect dose ranges and categories of treatm
serotonin reuptake inhibitor, SNRI selective norepinephrine reuptake inhibitor,example, additional nodes might be added to account for
combinations of the above therapies. Refinements in terms
of dosage stratifications, representation of differences in
implementation of physical/behavorial interventions or
other factors for all of the above interventions will be
made in collaboration with our team of clinical experts to
maximize clinical relevance once data collection is com-
pleted. Figure 1 presents a preliminary schematic diagram
of the treatments to be studied.
Outcomes
The primary outcomes of interest will be changes in the
intensity and frequency of hot flashes, with or without
night sweats. Changes in quality of life are also of interest
in terms of both symptom-specific and generic measures.
More specifically, changes of hot flash intensity are typic-
ally measured using scales such as the Hot Flash Daily
Related Interference Scale [18], the Greene Climacteric
Score [19], and the Modified Kupperman Index, [20]
amongst others; we will collect intensity outcomes re-
ported using any validated measure. The reporting of hot
flash frequency varies amongst trials and may be reported
as the percentage change in the frequency of hot flashes
from baseline, the mean number of hot flashes per day, orolors reflect treatments of similar groupings: red = pharmacologic
s and behavioral therapies. Lines reflect where comparisons may exist
d by study selection. Availability of outcomes can also impact network
ents will be established with the guidance of clinical experts. SSRI selective
CBT cognitive behavioral therapy
Table 1 Validated generic and symptom-specific scales for the
review
Outcome Related validated scales for data collection
Hot flash severity Scores with subscale for hot flashes severity
The Greene Climacteric Score
Hot Flash Daily Related Interference Scale
(HFDRIS)
Menopause Rating Scale (MRS)
The Mayo Clinic Hot flash Index
Generic quality of life EURO-QOL Linear Rating Scale
Hot Flash Daily Related Interference Scale
(HFDRIS)
Menopause Specific Quality of Life
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during the study; we will collect information for each of
these measures. Regarding symptom-specific and generic
quality of life measures, a range of scales have been used
in trials of hot flash interventions, including symptom-
specific measures for depression and sleep quality (e.g.,
the Center for Epidemiologic Studies Depression Scale
(CES-D) [21], Insomnia Severity Index [22]) as well as
generic measures (e.g., EuroQOL Linear Rating Scale
[23]); we will collect data from validated symptom-specific
and generic quality of life (QoL) scales for use in separate
analyses. Table 1 presents an overview of outcomes of
interest related to these clinical manifestations identified
by our research team that may be encountered during the
review. Secondary outcomes to be collected will include
measures related to adherence to cancer therapies and
harms associated with each treatment (e.g., drug toxicities,
discontinuation rates, suicidal behaviors).The Psychological General Well-Being
Index (PGWBI)
The Greene Climacteric Score
Menopause Rating Scale (MRS)
Depression symptoms Scores with subscale for depression
Menopause Rating Scale (MRS)
The profile of mood state (POMS)
Center for Epidemiologic StudiesStudy design
We will include randomized controlled trials, including
those of open-label design. Both parallel group and
crossover trials will be eligible. For crossover trials, we
will make use of data from the first study period due to
the potential for carryover effects. We will exclude
quasi-randomized and non-randomized studies.Depression Scale (CES-D)
Hamilton Depression Rating Scale
Montgomery-Åsberg Depression Rating Scale
The Primary Care Evaluation of Mental
Disorders (PRIME-MD)
Beck depression inventory-II (BDI-II)
Patient Health Questionnaire (PHQ) (9-PHQ,
and 2-PHQ self reported versions)
Raskin Depression Rating Scale
Sleep quality symptoms Scores with subscale for insomnia
Menopause Rating Scale (MRS)
Insomnia Severity Index (ISI)
Pittsburgh Sleep Quality Index
Epworth Sleepiness Scale
Basic Nordic Sleep Questionnaire (BNSQ)
Stanford Sleepiness Scale
Brief Insomnia Questionnaire
Validated scales of relevance related to hot flash severity, frequency, and other
outcomes of interested identified by participating experts as possibly arising in
studies relevant to the review are shown. If additional validated scales arise
during data collection, these will also be includedScreening and data extraction
Four reviewers will work in pairs to review abstracts
(Stage 1 screen) and full text reports (Stage 2 screen)
from search results independently and in duplicate
against the eligibility criteria using Distiller SR software
(Ottawa, Canada) to identify relevant articles. Both
stages of screening will begin with a calibration exercise
of approximately 50 abstracts and 10 full text reports to
ensure consistent application of eligibility criteria. Study
selection will be documented using a preferred reporting
items for systematic reviews and meta-analysis (PRISMA)
flow diagram [24]. Once all studies are identified, data ex-
traction will be performed using a standardized extraction
form which will be piloted by the reviewers on a small
number of studies. We will collect data related to key
items including patient demographics (age, sex, cancer
stage, duration of hot flashes before randomization, con-
current therapies, baseline hot flash frequency and sever-
ity, etc.), interventions (doses, frequency of administration,
setting, experience of therapist (when relevant), etc.), and
outcomes as described above. We will use the Cochrane
Risk of Bias Tool [25] for randomized controlled trials
(RCTs) to establish the risk of bias of each included study;
a summary of findings from these assessments will be pro-
vided, and they will also be used to consider sensitivity
analyses.Approach to evidence synthesis
Meta-analyses will be conducted in breast cancer and
prostate cancer patients separately and collectively. This
approach will enable inspection of the comparability of
effects of interventions in both populations while also
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of the available data. We will summarize characteristics
of included studies focusing on clinical (e.g., diagnosis,
age, sex, number of and types of prior therapies, dur-
ation of disease, time since onset of hot flashes) and
methodologic (e.g., risk of bias, design) homogeneity,
and we will review the distribution of these treatment ef-
fect modifiers across studies and comparisons in the
treatment network to assess the validity of the assump-
tions of homogeneity, similarity, and consistency [26].
Where there is homogeneity of important effect modi-
fiers, we will perform network meta-analyses (NMAs) to
compare interventions [14–16].
Prior to NMAs, we will perform pairwise meta-analyses
for each comparison in the treatment networks where
studies are available to explore for heterogeneity based on
the I2 statistic [27]. Fixed and random effects Bayesian
NMAs will be performed using a common heterogeneity
parameter as per established methods [15, 28]. Model fit
will be assessed by comparing the model’s residual devi-
ance with the number of unconstrained data points [28].
Selection between models will be based on deviance infor-
mation criteria (DIC), with a difference of five points sug-
gesting an important difference. Comparison of hot flash
frequency is commonly expressed as average number per
day and percentage change of frequency from baseline,
and both will be analyzed using a model for mean differ-
ences (MD). We will consider a model for standardized
mean differences (SMD) when assessing hot flash severity,
changes in general QoL, and symptom-specific QoL mea-
sures, as it will be of interest to explore benefits across re-
lated scales to maximize available data. All findings will be
presented with anchor-based (or if needed, distribution-
derived) minimally important differences to provide in-
sights on how estimated benefits compare to what may be
clinically relevant for patients. For outcomes analyzed
using an SMD summary measure, we will use established
methods [29, 30] to present results in minimal important
difference (MID) units such that findings are more inter-
pretable for knowledge users. All pairwise comparisons
between interventions will be expressed as MDs or SMDs
with corresponding 95 % credible intervals. If the structure
of treatment networks is judged to be sound (i.e., if there
does not exist a large number of comparisons in the net-
work with no available study data and there does not exist
a high number of comparisons informed by single studies),
we will supplement reporting of pairwise comparisons
with Surface Under the Cumulative Ranking (SUCRA)
curve values and median treatment rankings (with corre-
sponding 95 % credible intervals). The assumption of
consistency of direct and indirect data will be assessed by
fitting inconsistency models as described elsewhere [31],
which will include comparison of DIC from these models
with DIC from the corresponding consistency modelsalluded to above; scatterplots of residuals from both
models will also be inspected to identify potential stud-
ies contributing to inconsistency. All NMAs will be
performed using Winbugs software version 1.4.3 (MRC
Biostatistics). Model convergence will be assessed using
established methods including Gelman Rubin diagnos-
tics and inspection of Monte Carlo errors [28]. The
short nature of trials in this area is likely to be associ-
ated with a lack of reporting of adherence data for can-
cer therapies. If this data is available, we will employ
similar modeling approaches for binary data to com-
pare the numbers of patients maintaining adherence to
primary therapies. As the types of harms are likely to
vary due to the different types of interventions being
compared, meta-analyses for specific harms may not be
feasible. If this is true, we will present descriptions of
the harms for each intervention.
Regarding sources of heterogeneity, we will explore
subgroup analyses and meta-regression analyses to ad-
dress the impact of covariates on our findings to estab-
lish their robustness [32, 33]. Based on clinical expertise
and the existing literature, the following group-level fac-
tors will be explored: percentage of male participants,
average patient age, percentage receiving concurrent
hormone therapy, percentage with history of chemother-
apy, average time since first hot flash, and average time
since cancer diagnosis; others may be added if factors
seen as important by our clinical experts emerge during
data collection and review of study characteristics. Re-
garding network structure, we will explore sensitivity
analyses using alternative geometries [34] which may in-
clude refining how interventions are reflected in the
treatment network. For example, if experts on the team
consider doses of a drug to be importantly different
across studies, these treatments will be considered dis-
tinct from each other in analyses to maximize clinical
relevance. Conversely, analyses lumping treatments into
one group (e.g., all SSRIs together) may also be consid-
ered. Findings from all analyses will be reported. For
connections in the treatment network consisting of ten
studies or more, we will review funnel plots to explore
for the potential presence of publication bias.Reporting of review findings
Reporting of findings from this systematic review will
adhere to recommendations from the PRISMA exten-
sion statement for network meta-analysis [35]. Recom-
mended graphical approaches including forest plots,
league tables, and rank-o-grams will be used [36]. We
will prepare a summary of the geometries of the net-
works in breast and prostate cancer as seen for other
conditions [37–39] to provide insight on future research
needs for trialists.
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Many different interventions including natural health prod-
ucts, drugs, physical activities, and behavioral therapies
have been studied in hopes of identifying novel approaches
to reducing the impact that vasomotor symptoms such as
hot flashes have on patients’ quality of life. There is a need
to compare hot flash treatments in cancer patients to
inform guidance, improve care, and share information
with patients. Given that many non-hormonal treat-
ments exist, a network meta-analysis [14–16] is needed
to establish relative benefits for patients. We will employ
dedicated methods to enhance interpretability for patients
and decision-makers [40]. We will share our findings with
Cancer Care Ontario’s Program in Evidence Based Care,
which will incorporate them into future clinical guidance
in their Supportive Care program.
Currently, guidance related to interventions for man-
agement of hot flashes in breast and prostate cancers is
limited and inconsistent. While reviews comparing some
of the above interventions have been conducted, several
are in need of updating, and thus far, no network meta-
analyses to compare the benefits of all existing interven-
tions have been performed to address this knowledge
gap. By conducting the proposed review, we hope to im-
prove clinicians’ and patients’ awareness regarding the
relative benefits of different interventions to manage hot
flashes. We intend to address this important knowledge
gap in the management of supportive care for patients
with breast and prostate cancers by conducting this
study to (1) generate rigorous scientific publications de-
scribing our findings in open access journals to target
clinicians, nurses, and patients alike; (2) bring our find-
ings to the table for use amongst clinical guidance devel-
opers at Cancer Care Ontario for development of future
guidance; and (3) generate targeted lay summaries of our
findings for clinicians and patients to make our results
accessible. We believe our planned deliverables are cap-
able of impacting future management of breast and
prostate cancer survivors who experience hot flashes.Additional file
Additional file 1: Draft search. Description: Contains the search
strategy to be used for the planned systematic review. (DOCX 17 kb)Abbreviations
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